# 2026-06283: NIH Hands Eye-Saving Peptides to Biotech Firm Exclusive Rights

2026-06283, Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration, is a Federal Register notice from Health and Human Services Department, National Institutes of Health published 2026-04-01, effective 2026-04-01; PRIA reads it as touching household money (as of 2026-06-08).

- Canonical: https://policyrisk.com/federal-register/2026-06283
- As of: 2026-06-08
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2026-06283
- Title: Prospective Grant of an Exclusive Patent License: Pigment Epithelium-Derived Factor (PEDF) Peptides and Use for Treating Retinal Degeneration
- Type: Notice
- Agencies: Health and Human Services Department; National Institutes of Health
- Citation: 91 FR 16205
- Published: 2026-04-01
- Effective: 2026-04-01
- Comments close: 2026-04-16
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-08

## In one line

NIH Hands Eye-Saving Peptides to Biotech Firm Exclusive Rights

## Summary

The National Eye Institute plans to give Perpetual Biosciences, Inc. an exclusive license to use special PEDF peptides to treat eye diseases that cause vision loss. This means the company will have the sole right to develop and sell this promising treatment, potentially helping millions with retinal degeneration. If you want to comment or apply for a license, act fast—submissions close April 16, 2026!

## Abstract

The National Eye Institute, an institute of the National Institutes of Health, United States Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the patent applications listed in the SUPPLEMENTARY INFORMATION section of this notice to Perpetual Biosciences, Inc., a company located in New York, NY.

## Effects PRIA read

- Exclusive License for PEDF Eye Treatment: benefit, high. The National Eye Institute is considering granting Perpetual Biosciences, Inc. an exclusive, royalty-bearing license (possibly worldwide) to develop and sell chemically synthesized PEDF peptide therapeutics for human eye diseases, including retinitis pigmentosa, glaucoma, and age-related macular de…

## Related documents

- [2026-20771](https://policyrisk.com/federal-register/2026-20771): Center for Scientific Review; Notice of Closed Meetings, 2026-10-09
- [2026-20705](https://policyrisk.com/federal-register/2026-20705): Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Antibody Specifically Binding to Severe Fever With…, 2026-10-09
- [2026-20424](https://policyrisk.com/federal-register/2026-20424): National Cancer Institute; Notice of Meeting, 2026-10-06
- [2026-20365](https://policyrisk.com/federal-register/2026-20365): Center For Scientific Review; Notice of Closed Meetings, 2026-10-05
- [2026-20151](https://policyrisk.com/federal-register/2026-20151): Notice of NIH Tribal Consultations and Listening Session, 2026-10-01
- [2026-19719](https://policyrisk.com/federal-register/2026-19719): Center for Scientific Review; Amended Notice of Meeting, 2026-09-28

## Sources
- [2026-06283 on federalregister.gov](https://www.federalregister.gov/documents/2026/04/01/2026-06283/prospective-grant-of-an-exclusive-patent-license-pigment-epithelium-derived-factor-pedf-peptides-and)
- [2026-06283 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2026-04-01/pdf/2026-06283.pdf)

## Related
- [Previous: 2026-06282, Brightwood Capital SBIC IV, LP; Notice Seeking Exemption Under Section 312 of t…](https://policyrisk.com/federal-register/2026-06282)
- [Next: 2026-06284, Statement of Organization, Functions, and Delegations of Authority; Office of T…](https://policyrisk.com/federal-register/2026-06284)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2026-06283 (as of 2026-06-08).